Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR2 | P50052 | 4/20 | 0.43 |
| ▸ | AGTR1 | P30556 | 4/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8841897 | 0.96 | AGTR2 (0.41) | AGTR2AGTR1NPC1CYP1A2CYP3A4 | |
| SCHEMBL8842025 | 0.95 | AGTR1 (0.50) | AGTR2AGTR1 | |
| SCHEMBL8842218 | 0.94 | AGTR1 (0.47) | AGTR2AGTR1 | |
| SCHEMBL8841756 | 0.91 | AGTR1 (0.48) | AGTR2AGTR1ADORA3 | |
| SCHEMBL9529156 | 0.91 | AGTR2 (0.49) | AGTR2AGTR1NPC1CYP1A2CYP3A4 | |
| SCHEMBL8841497 | 0.91 | AGTR1 (0.45) | AGTR2AGTR1ADORA3 | |
| SCHEMBL8841879 | 0.88 | AGTR1 (0.48) | AGTR2AGTR1 | |
| SCHEMBL8841871 | 0.88 | AGTR1 (0.46) | AGTR2AGTR1 | |
| SCHEMBL8841304 | 0.87 | AGTR1 (0.48) | AGTR2AGTR1 | |
| SCHEMBL8841835 | 0.87 | AGTR1 (0.40) | AGTR2AGTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5602153-A | Method of using 1-arylheteroarylalkyl substituted-1H-1,2,4-triazole compounds for treatment of a giaucoma disorder | G.D. SEARLE & CO. (US) | 1997-02-11 | — | — | US | disclosed |
| US-5563139-A | Method of using 1-arylheteroarylalkyl substituted-1H-1,2,4-triazole compounds for treatment of a glaucoma disorder | G. D. SEARLE & CO. (US) | 1996-10-08 | — | — | US | disclosed |
| EP-0508445-B1 | 1-Arylheteroarylalkyl substituted-1H-1,2,4-triazole compounds for treatment of circulatory disorders | SEARLE & CO (US) | 1996-06-12 | — | — | EP | disclosed |
| EP-0619819-B1 | 1-ARYLHETEROARYLALKYL SUBSTITUTED-1H-1,2,4-TRIAZOLE COMPOUNDS FOR TREATMENT OF CIRCULATORY DISORDERS | SEARLE & CO (US) | 1996-06-12 | — | — | EP | disclosed |
| EP-0619819-A1 | 1-ARYLHETEROARYLALKYL SUBSTITUTED-1H-1,2,4-TRIAZOLE COMPOUNDS FOR TREATMENT OF CIRCULATORY DISORDERS. | SEARLE & CO (US) | 1994-10-19 | — | — | EP | disclosed |
| WO-1992018092-A2 | 1-ARYLHETEROARYLALKYL SUBSTITUTED-1H-1,2,4-TRIAZOLE COMPOUNDS FOR TREATMENT OF CIRCULATORY DISORDERS | G.D. SEARLE & CO. (US) | 1992-10-29 | — | — | WO | disclosed |
| EP-0508445-A1 | 1-Arylheteroarylalkyl substituted-1H-1,2,4-triazole compounds for treatment of circulatory disorders | G.D. Searle & Co. (US) | 1992-10-14 | — | — | EP | disclosed |
| US-5155117-A | Hypotensive agents | G. D. SEARLE & CO. (US) | 1992-10-13 | — | — | US | disclosed |